Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

Authors

  • Anouk K. M. Claessens Department of Medical Oncology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
  • Jan J. V. Busschbach Department of Psychiatry, Section of Medical Psychology and Psychotherapy, Erasmus Medical Centre, Rotterdam, The Netherlands
  • Bram L. T. Ramaekers Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands
  • Frans L. G. Erdkamp Department of Medical Oncology, Zuyderland Medical Centre, Geleen, The Netherlands
  • Jeanette M. Bouma Department of Trial Registration, Comprehensive Cancer Centre the Netherlands, Rotterdam, The Netherlands
  • A. Elise van Leeuwen-Stok Dutch Breast Cancer Research Group, BOOG Study Center, Amsterdam, The Netherlands
  • Vivianne C. G. Tjan-Heijnen Department of Medical Oncology, GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
  • Monique E. M. M. Bos Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, The Netherlands

DOI:

https://doi.org/10.1080/0284186X.2022.2033832

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-05-04

How to Cite

Claessens, A. K. M., Busschbach, J. J. V., Ramaekers, B. L. T., Erdkamp, F. L. G., Bouma, J. M., van Leeuwen-Stok, A. E., … Bos, M. E. M. M. (2022). Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. Acta Oncologica, 61(5), 619–624. https://doi.org/10.1080/0284186X.2022.2033832

Issue

Vol. 61 No. 5 (2022): Acta Oncologica

Section

Articles